Skip to main content

Table 2 Univariate and multivariate analysis of progression-free and overall survival

From: Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study

 

PFS

OS

Clinical characteristics

M

p*

HR

95%CI

p†

M

p*

HR

95% CI

p†

Age, years

 ≤70

10.0

0.270

   

28.0

0.004

1

 

0.017

 >70

14.0

    

22.0

 

1.47

1.07-2.01

Gender

 Female

12.0

0.481

   

24.0

0.752

   

 Male

11.0

    

25.0

   

Smoking

 No

12.0

0.365

   

27.0

0.359

   

 Yes

11.0

    

23.0

   

ECOG PS

 0/1

13.0

<0.0001

1

 

0.001

29.0

<0.0001

1

 

0.001

 ≥2

7.0

 

1.80

1.26-2.56

 

12.0

 

1.88

1.28-2.75

Brain metastasis

 No

14.0

<0.0001

1

 

0.001

30.0

<0.0001

1

 

0.026

 Yes

9.0

 

1.65

1.22-2.23

 

19.0

 

1.46

1.05-2.02

Disease status

 Recurrent

17.0

0.005

1

 

0.059

48.0

<0.0001

1

 

0.007

 Primary metastatic

11.0

 

1.46

0.99-2.15

 

23.0

 

1.86

1.18-2.92

Type of TKI

 1st generation

10.0

0.179

   

23.0

0.037

1

 

0.595

 Afatinib

14.0

    

30.0

 

0.90

0.62-1.31

Type of EGFR mutation

 Others

9.0

0.138

   

22.0

0.047

1

 

0.028

 Exon 19 deletion

12.0

    

30.0

 

0.72

0.54-0.97

  1. PFS Progression-free survival, OS Median overall survival, HR hazard ratio, CI Confidence interval, ECOG Eastern Cooperative Oncology Group, PS Performance status, TKI Tyrosine kinase inhibitor, EGFR Epidermal growth factor receptor; M Months (median), p p-value
  2. *Log-rank test †Cox proportional-hazards regression model
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us